Importantly, results of the recently published TOPAZ‐1 trial,17 which evaluated the efficacy of Durvalumab (an anti‐PD‐L1 agent) and chemotherapy vs chemotherapy alone in advanced biliary tract cancers, demonstrated a promising improvement in survival for patients receiving the anti‐PD‐L1 antibody. The gene discussed is CD274; the disease is biliary tract cancer.